{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:41:35Z","timestamp":1779266495946,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T00:00:00Z","timestamp":1481500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T00:00:00Z","timestamp":1481500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/bmt.2016.282","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T10:04:41Z","timestamp":1481537081000},"page":"372-380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation"],"prefix":"10.1038","volume":"52","author":[{"given":"M","family":"van Gelder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L C","family":"de Wreede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Karas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N S","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Michallet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N H","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Vitek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1","family":"Urbano-Isp\u00edzua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Volin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Putter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"van Biezen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Henseler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Chronic Malignancy Working Party","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,12]]},"reference":[{"key":"BFbmt2016282_CR1","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17: 768\u2013778.","journal-title":"Lancet Oncol"},{"key":"BFbmt2016282_CR2","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","volume":"32","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM . Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol 2014; 32: 3039\u20133047.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR3","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497\u20132506.","journal-title":"Blood"},{"key":"BFbmt2016282_CR4","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","volume":"21","author":"J Schetelig","year":"2003","unstructured":"Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747\u20132753.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR5","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1182\/blood-2003-12-4321","volume":"104","author":"M Ritgen","year":"2004","unstructured":"Ritgen M, Stilgenbauer S, Von Neuhoff N, Humpe A, Bruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600\u20132602.","journal-title":"Blood"},{"key":"BFbmt2016282_CR6","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","volume":"26","author":"ML Sorror","year":"2008","unstructured":"Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26: 4912\u20134920.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR7","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116: 2438\u20132447.","journal-title":"Blood"},{"key":"BFbmt2016282_CR8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/leu.2012.228","volume":"27","author":"JR Brown","year":"2013","unstructured":"Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013; 27: 362\u2013369.","journal-title":"Leukemia"},{"key":"BFbmt2016282_CR9","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","volume":"124","author":"P Dreger","year":"2014","unstructured":"Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014; 124: 3841\u20133849.","journal-title":"Blood"},{"key":"BFbmt2016282_CR10","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015; 125: 2062\u20132067.","journal-title":"Blood"},{"key":"BFbmt2016282_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1182\/blood-2015-03-585091","volume":"126","author":"A Mato","year":"2015","unstructured":"Mato A, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N et al. Favorable outcomes in CLL pts with alternate kinase inhibitors following ibrutinib or idelalisib discontinuation: results from a large multi-center study. Blood 2015; 126: 719.","journal-title":"Blood"},{"key":"BFbmt2016282_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/blood-2015-04-639138","volume":"126","author":"J Jones","year":"2015","unstructured":"Jones J, Mato AR, Coutre S, Wierda W, Choi MY, Davids MS et al. Preliminary results of a phase 2, open-label study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with chronic lymphocytic leukemia relapsed after or refractory to ibrutinib or idelalisib therapy. Blood 2015; 126: 715.","journal-title":"Blood"},{"key":"BFbmt2016282_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood-2015-06-639161","volume":"126","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Wierda W, Jones J, O'Brien S, Brown JR, Schuh A et al. The Bruton tyrosine kinase (Btk) inhibitor ACP-196: marked activity in relapsed\/refractory CLL with a favorable safety profile. Blood 2015; 126: 831.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BFbmt2016282_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/bmt.2012.282","volume":"48","author":"S Iacobelli","year":"2013","unstructured":"Iacobelli S . Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013; 48 (Suppl 1): S1\u201337.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016282_CR15","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1002\/sim.2414","volume":"24","author":"J Stare","year":"2005","unstructured":"Stare J, Pohar M, Henderson R . Goodness of fit of relative survival models. Stat Med 2005; 24: 3911\u20133925.","journal-title":"Stat Med"},{"key":"BFbmt2016282_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cmpb.2006.01.004","volume":"81","author":"M Pohar","year":"2006","unstructured":"Pohar M, Stare J . Relative survival analysis in R. Comput Methods Programs Biomed 2006; 81: 272\u2013278.","journal-title":"Comput Methods Programs Biomed"},{"key":"BFbmt2016282_CR17","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/sim.3844","volume":"29","author":"MA Nicolaie","year":"2010","unstructured":"Nicolaie MA, van Houwelingen HC, Putter H . Vertical modeling: a pattern mixture approach for competing risks modeling. Stat Med 2010; 29: 1190\u20131205.","journal-title":"Stat Med"},{"key":"BFbmt2016282_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.bbmt.2014.05.020","volume":"20","author":"RM Sobecks","year":"2014","unstructured":"Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M et al. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant 2014; 20: 1390\u20131398.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016282_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.bbmt.2013.11.032","volume":"20","author":"M Sabloff","year":"2014","unstructured":"Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR et al. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant 2014; 20: 421\u2013424.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016282_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","volume":"28","author":"PJ Martin","year":"2010","unstructured":"Martin PJ, Counts GW Jr., Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011\u20131016.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.2009.26.7757","volume":"28","author":"JM Goldman","year":"2010","unstructured":"Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010; 28: 1888\u20131895.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR22","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230\u20132239.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR23","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","volume":"110","author":"S Bhatia","year":"2007","unstructured":"Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784\u20133792.","journal-title":"Blood"},{"key":"BFbmt2016282_CR24","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1200\/JCO.2005.04.569","volume":"23","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819\u20133829.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","volume":"20","author":"EJ Chow","year":"2014","unstructured":"Chow EJ, Wong K, Lee SJ, Cushing-Haugen KL, Flowers ME, Friedman DL et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20: 794\u2013800.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2016282_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.exphem.2013.07.003","volume":"42","author":"PA Pophali","year":"2014","unstructured":"Pophali PA, Klotz JK, Ito S, Jain NA, Koklanaris E, Le RQ et al. Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol 2014; 42: 83\u201389.","journal-title":"Exp Hematol"},{"key":"BFbmt2016282_CR27","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1182\/blood-2009-06-229369","volume":"116","author":"CL Sun","year":"2010","unstructured":"Sun CL, Kawashima T, Leisenring W, Robison LL, Baker KS, Weisdorf DJ et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010; 116: 3129\u20133139.","journal-title":"Blood"},{"key":"BFbmt2016282_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/bmt.2015.150","volume":"50","author":"M Hahn","year":"2015","unstructured":"Hahn M, Bottcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P et al. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplant 2015; 50: 1279\u20131285.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016282_CR29","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2012.42.3038","volume":"30","author":"KL Syrjala","year":"2012","unstructured":"Syrjala KL, Martin PJ, Lee SJ . Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol 2012; 30: 3746\u20133751.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/bmt.2012.5","volume":"47","author":"NS Majhail","year":"2012","unstructured":"Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337\u2013341.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016282_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/asheducation-2014.1.495","volume":"2014","author":"S Bhatia","year":"2014","unstructured":"Bhatia S . Caring for the long-term survivor after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2014; 2014: 495\u2013503.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbmt2016282_CR32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","volume":"19","author":"P Dreger","year":"2005","unstructured":"Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029\u20131033.","journal-title":"Leukemia"},{"key":"BFbmt2016282_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525\u2013530.","journal-title":"Nature"},{"key":"BFbmt2016282_CR34","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1200\/JCO.2014.58.6750","volume":"33","author":"U Rozovski","year":"2015","unstructured":"Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S et al. Outcomes of patients with chronic lymphocytic leukemia and Richter's transformation after transplantation failure. J Clin Oncol 2015; 33: 1557\u20131563.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2014.60.3282","volume":"33","author":"E Montserrat","year":"2015","unstructured":"Montserrat E, Dreger P . Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation. J Clin Oncol 2015; 33: 1527\u20131529.","journal-title":"J Clin Oncol"},{"key":"BFbmt2016282_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/bmt.2015.339","volume":"51","author":"CS Link","year":"2016","unstructured":"Link CS, Heidenreich F, R\u00fccker-Braun E, Schmiedgen M, Reinhardt J, Oelschl\u00e4gel U et al. Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 793\u2013798.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2016282_CR37","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1182\/blood.V124.21.4697.4697","volume":"124","author":"S Coutre","year":"2014","unstructured":"Coutre S, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ et al. Safety and efficacy of ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood 2014; 124: 4697.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2016282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016282","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2016282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T15:09:46Z","timestamp":1648048186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2016282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,12]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFbmt2016282"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2016.282","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,12]]},"assertion":[{"value":"18 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}